Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback